BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28664909)

  • 1. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics.
    Argyriou AA; Bruna J; Genazzani AA; Cavaletti G
    Nat Rev Neurol; 2017 Aug; 13(8):492-504. PubMed ID: 28664909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced peripheral neurotoxicity.
    Cavaletti G; Marmiroli P
    Curr Opin Neurol; 2015 Oct; 28(5):500-7. PubMed ID: 26197027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies.
    Chua KC; El-Haj N; Priotti J; Kroetz DL
    Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1(Suppl 1):60-74. PubMed ID: 34481421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.
    Travis LB; Fossa SD; Sesso HD; Frisina RD; Herrmann DN; Beard CJ; Feldman DR; Pagliaro LC; Miller RC; Vaughn DJ; Einhorn LH; Cox NJ; Dolan ME;
    J Natl Cancer Inst; 2014 Mar; 106(5):. PubMed ID: 24623533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.
    Cavaletti G; Alberti P; Marmiroli P
    Lancet Oncol; 2011 Nov; 12(12):1151-61. PubMed ID: 21719347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.
    Cavaletti G
    J Peripher Nerv Syst; 2014 Jun; 19(2):66-76. PubMed ID: 24976572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity.
    Pozzi E; Alberti P
    Methods Mol Biol; 2022; 2547():95-140. PubMed ID: 36068462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.
    Cavaletti G; Frigeni B; Lanzani F; Mattavelli L; Susani E; Alberti P; Cortinovis D; Bidoli P
    Eur J Cancer; 2010 Feb; 46(3):479-94. PubMed ID: 20045310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic factors influencing the development of vincristine-induced neurotoxicity.
    Pozzi E; Fumagalli G; Chiorazzi A; Canta A; Cavaletti G
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):215-226. PubMed ID: 33283553
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.
    McCrary JM; Goldstein D; Boyle F; Cox K; Grimison P; Kiernan MC; Krishnan AV; Lewis CR; Webber K; Baron-Hay S; Horvath L; Park SB;
    Support Care Cancer; 2017 Nov; 25(11):3485-3493. PubMed ID: 28589310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced peripheral neuropathy: A current review.
    Staff NP; Grisold A; Grisold W; Windebank AJ
    Ann Neurol; 2017 Jun; 81(6):772-781. PubMed ID: 28486769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Reduction of Mitochondria Complex I Subunits is Protective against Cisplatin-Induced Neurotoxicity in
    Groen CM; Podratz JL; Pathoulas J; Staff N; Windebank AJ
    J Neurosci; 2022 Feb; 42(5):922-937. PubMed ID: 34893548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.
    Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA
    Cancer Treat Rev; 2016 Nov; 50():118-128. PubMed ID: 27664395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
    Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
    Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-Related Neurotoxicity.
    Taillibert S; Le Rhun E; Chamberlain MC
    Curr Neurol Neurosci Rep; 2016 Sep; 16(9):81. PubMed ID: 27443648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms.
    Argyriou AA; Bruna J; Park SB; Cavaletti G
    Expert Rev Neurother; 2020 Oct; 20(10):1005-1016. PubMed ID: 32667212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic neuropathies: Chemotherapy Induced Peripheral Neurotoxicity.
    Alberti P; Cavaletti G; Cornblath DR
    Curr Opin Neurol; 2019 Oct; 32(5):676-683. PubMed ID: 31306214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue.
    Cavaletti G; Alberti P; Argyriou AA; Lustberg M; Staff NP; Tamburin S;
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S6-S12. PubMed ID: 31647155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?
    Cavaletti G; Marmiroli P; Renn CL; Dorsey SG; Serra MP; Quartu M; Meregalli C
    Neurotherapeutics; 2021 Oct; 18(4):2324-2336. PubMed ID: 34668147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.